The current financial score of Abbott Laboratories is 8.81. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.59B, representing a year-over-year increase of 13.02%, while its net profit experienced a year-over-year increase of 47.84%.
The current valuation score of Abbott Laboratories is 8.38. Its current P/E ratio is 27.89, which is 38.75% below the recent high of 38.70 and 48.29% above the recent low of 14.42.
The current earnings forecast score of Abbott Laboratories is 8.48. The average price target is 121.39, with a high of 136.00 and a low of 103.00.
The current price momentum score of Abbott Laboratories is 3.30. Currently, the stock price is trading between the resistance level at 106.38 and the support level at 94.56, making it suitable for range-bound swing trading.
The current institutional shareholding score of Abbott Laboratories is 7.00. The latest institutional shareholding proportion is 71.75%, representing a quarter-over-quarter decrease of 12.31%.
The current risk assessment score of Abbott Laboratories is 8.54. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.